SKAN Group AG
SIX:SKAN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (35.6), the stock would be worth CHf98.18 (105% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 17.4 | CHf48 |
0%
|
| 3-Year Average | 35.6 | CHf98.18 |
+105%
|
| 5-Year Average | 36.2 | CHf99.98 |
+108%
|
| Industry Average | 20.7 | CHf57.14 |
+19%
|
| Country Average | 16.1 | CHf44.34 |
-8%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CH |
|
SKAN Group AG
SIX:SKAN
|
1.1B CHF | 17.4 | 67.4 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 1 773.3 | 4 278.7 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
197.4B USD | 28.3 | 29.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
137.5B USD | 23.6 | 38.1 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 36.2 | 46.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
35.1B CHF | 32.5 | -124.8 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
294B CNY | 15.1 | 15.4 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.5B USD | 25.9 | 26.8 | |
| US |
|
Waters Corp
NYSE:WAT
|
32.9B USD | 50.9 | 51.2 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.8B USD | 15.7 | 22 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27B USD | 30.3 | 31 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 16.1 |
| 70th Percentile | 20.8 |
| Max | 647 |
Other Multiples
SKAN Group AG
Glance View
SKAN Group AG, headquartered in Switzerland, has carved out its niche as a leading innovator in the realm of contamination control for aseptic environments. The company's history traces back to its founding in 1968, following the rapid advancements in the pharmaceutical and biotechnology sectors. SKAN has since developed a sterling reputation for its pioneering work in isolator technology, offering solutions that ensure the highest standards of sterility and safety critical to these industries. The company designs and manufactures isolators, which are essentially sealed environments that provide contamination-free zones for the processing of materials or production of pharmaceuticals, ensuring that even the most sensitive products are handled with stringent safety measures. This focus on high-tech, specialized equipment forms the backbone of SKAN's revenue model. By providing bespoke solutions tailored to the unique requirements of its clients, SKAN taps into the lucrative markets of pharmaceutical production and research, biotechnology companies, and laboratories that demand high-performance contamination barriers. Beyond just the sale of equipment, SKAN also offers a comprehensive suite of services, including installation, validation, maintenance, and training, ensuring a steady flow of income as these businesses need continual updates and technical support for their critical infrastructure. The demand for stricter health regulations and more advanced pharmaceuticals continues to rise, positioning SKAN Group AG as a pivotal player in this essential industry, capitalizing on its expertise to ensure both safety and compliance for its customers worldwide.